Tongji Medical Announces Global Filing of IPO Prospectus for Its Breakthrough GBS Endoscopic Duodenal Bypass System – The World’s First Class III Innovative Medical Device for Metabolic Disease Intervention
Tongee
Medical Device R&D Company in the Field of Metabolic Diseases
Metabolic Diseasesis the primary cause of suboptimal health status globally, and its prevention and treatment presentSignificant Unmet Clinical Needs. Globally, there are up to 2.2 billion overweight individuals and 700 million obese individuals, with 3.4 million deaths annually attributed to conditions related to obesity or overweight. Obesity has become a major public health issue in China, which now ranks first worldwide in both the incidence rate and growth rate of overweight and obesity, making it the country with the largest number of overweight and obese individuals. It is projected that by 2030, the prevalence of overweight and obesity among Chinese adults will reach 61%.
Since its inception, Tongee Medical has always adhered to the mission of exploring new methods for treating metabolic diseases. Addressing the challenges and pain points in the field of metabolic disease treatment, Tongee MedicalFocused on developing interventional therapies for the digestive tract, along with related medical devices, disease management, and solutions, its gastric bypass stent system is the first globally innovative product approved for market launch., this therapy has opened up new avenues for the treatment of metabolic diseases.
Gastric Bypass Stent SystemAs an innovative therapy, it offers advantages over traditional treatment options, including being minimally invasive, easy to operate, non-damaging to human anatomical structures, easily removable, and reusable for reimplantation. It achieves a conceptual leap from “reducing intake” to “reducing absorption,” pioneers a new therapeutic pathway in the field of weight management, fills the gap between pharmacological weight loss and bariatric surgery, and serves as an important complement to medical weight management, thereby forming“Lifestyle Intervention → Pharmacotherapy → Interventional Therapy → Surgical Procedure” Stepwise ApproachWeight Loss Landscape.
In January this year, the “Gastric Bypass Stent System” produced by Hangzhou Tongee Medical Technology Co., Ltd. (hereinafter referred to as “Tongee Medical”),Approved for the World’s First Class III Medical Device Certificate for Innovative Endoluminal Interventional Treatment of Obesity!The approval of this product marks a significant step forward for China, and indeed the world, in the field of interventional therapy for metabolic diseases. It signifies a shift from an era where overseas technologies led the industry to one where Chinese innovative technologies are emerging on the international stage.Gastric Bypass Stent System: A China-Originated, World-Leading Innovative Technology, this approval not only highlights the continuous enhancement of China’s original R&D capabilities but will also drive technological innovation across the entire Chinese healthcare industry.
On Wednesday, May 22, at 19:30, the 62nd session of VCBeat Selects New Product Appreciation invitesZuo Yuxing, Founder & CEO of Tongee Medical、Chen Jiahao, Deputy General Manager & CMO of Tongee Medical、Li Wenyu, Technical Director of Tongee Medical, bringing“ China's Original World's First Innovative Endoscopic Weight-Loss Therapy: Gastric Bypass Stent SystemSystem”product promotion.
The World’s First Class III Innovative Medical Device Registration Certificate for Endoscopic Interventional Treatment of Obesity
NMPA Registration No. 20243130104
1. Designed to conform to human physiological anatomy, it can be deployed within 5–10 minutes during routine painless gastroscopy and easily removed after 3–6 months of implantation, ensuring safety and efficacy.
2. It not only enables rapid weight loss with long-term maintenance of efficacy, but also effectively treats obesity-associated non-alcoholic steatohepatitis (NASH) and type 2 diabetes.
3. Reinsertable; can also be placed preoperatively in conjunction with surgical procedures to improve surgical success rates and reduce the incidence of adverse events.
“Remodeling” Gut Ecology: Multifactorial Synergy in Promoting Weight Loss and Glycemic Control
Chyme remains within the sleeve, while bile and pancreatic juices are outside the sleeve; the two do not come into contact or mix to initiate chemical digestion until the mid-jejunum. The gastric bypass stent system reduces the effective intestinal length available for the initiation of digestion.
After the gastric bypass stent system isolates the small intestine from food stimulation, the exclusion of nutrient contact promotes remodeling of intestinal morphology and mucosal structure, as well as accelerated turnover of gastrointestinal cells.
The gastric bypass stent system enables distal intestinal L cells to have greater exposure to nutrients, thereby efficiently secreting large amounts of peptides such as GLP-1, GLP-2, and PYY, which further suppress appetite and promote glycemic control and weight loss.
Following the implantation of the gastric bypass stent system, a greater amount of bile acids and nutrients enter the distal small intestine, ileocecal segment, and colon, thereby improving the distribution of intestinal probiotics and significantly increasing their proportion.
Scan the QR code on the poster to add the assistant and reserve a spot for the live broadcast.
Zuo Yuxing, Founder & CEO of Tongee Medical
With 7 years of clinical practice in gastroenterology, 16 years of sales experience with top-tier international medical brands, and 8 years of corporate management experience; leveraging extensive expertise in clinical medicine, marketing, and innovative R&D, along with a keen global perspective, he has guided Tongee Medical to secure investment from multiple capital firms, ushering in a new era of interventional therapy for metabolic diseases.
Chen Jiahao, Deputy General Manager & CMO of Tongee Medical
25 years of experience in pharmaceutical and medical device sales and marketing management, with expertise in internet healthcare marketing, business planning, and the development of innovative healthcare business models. Proven track record in high-performance management, with exceptional communication, organizational, and team leadership skills. Extensive project management experience, specializing in the establishment of Sales Force Effectiveness (SFE) systems and training frameworks.
Li Wenyu, Technical Director at Tongee Medical
Ph.D. in Materials Science from Zhejiang University, Senior Engineer; dedicated to the research of biomedical materials for 15 years; authored over 10 SCI-indexed papers; filed more than 40 invention patents (with 17 granted); led or participated in nearly 10 national and provincial science and technology projects; and spearheaded the development of multiple internationally leading Class III passive medical devices.
Tongee Medical is a national high-tech enterprise dedicated to building an innovative platform for gastrointestinal interventional therapies, related medical devices, and disease management solutions. Adhering to its vision of pioneering new pathways for treating metabolic diseases and its mission to help patients worldwide alleviate suffering, regain health, and reclaim their well-being, the company has successfully developed multiple advanced medical technologies targeting metabolic conditions such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
Currently, the company has established multiple technology platforms and possesses a comprehensive system for R&D, quality control, production, and supply chain management, having obtained ISO 13485 certification. As of April 2024, Tongee Medical had nearly 10 projects under development, filed over 90 patent applications, and was conducting clinical trials at various stages for multiple products in more than 20 renowned hospitals.
Tongee Medical is ushering in a new era of interventional therapy for metabolic diseases, driven by innovation and centered on patients and physicians!
“Artery Select New Product Showcase” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is to empower every milestone launch of innovative medical products.
Scan the QR code below to contact the assistant and schedule a live stream.
(If already added, please proactively contact the assistant)
